Endogenous and pharmacologic targeting of the STING pathway in cancer immunotherapy

Cytokine. 2016 Jan:77:245-7. doi: 10.1016/j.cyto.2015.08.258. Epub 2015 Aug 24.

Authors

Leticia Corrales¹, Thomas F Gajewski²

Affiliations

¹ Department of Pathology, The University of Chicago, Chicago, IL, USA.
² Department of Pathology, The University of Chicago, Chicago, IL, USA; Department of Medicine, Section of Hematology/Oncology, The University of Chicago, Chicago, IL, USA. Electronic address: tgajewsk@medicine.bsd.uchicago.edu.

No abstract available

Keywords: STING pathway; Tumor immunology; Type I IFN.

Publication types

Research Support, N.I.H., Extramural

MeSH terms

Adaptive Immunity / immunology
Antigen-Presenting Cells / immunology
Antigen-Presenting Cells / metabolism
Humans
Immunity, Innate / immunology
Immunotherapy / methods*
Membrane Proteins / immunology*
Membrane Proteins / metabolism
Models, Immunological
Neoplasms / immunology*
Neoplasms / therapy*
Signal Transduction / immunology*
T-Lymphocytes / immunology
T-Lymphocytes / metabolism
Tumor Microenvironment / immunology

Substances

Membrane Proteins
STING1 protein, human

Grants and funding